Gilead Sciences (GILD) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Gilead Sciences Revenue Highlights

Latest Revenue (Y)

$28.75B

Latest Revenue (Q)

$7.55B

Main Segment (Y)

Products, Other HIV

Main Geography (Y)

UNITED STATES

Gilead Sciences Revenue by Period

Gilead Sciences Revenue by Year

Date	Revenue	Change
2024-12-31	$28.75B	6.04%
2023-12-31	$27.12B	-0.60%
2022-12-31	$27.28B	-0.09%
2021-12-31	$27.30B	10.60%
2020-12-31	$24.69B	9.98%
2019-12-31	$22.45B	1.46%
2018-12-31	$22.13B	-15.24%
2017-12-31	$26.11B	-14.09%
2016-12-31	$30.39B	-6.89%
2015-12-31	$32.64B	31.13%
2014-12-31	$24.89B	122.20%
2013-12-31	$11.20B	15.45%
2012-12-31	$9.70B	15.71%
2011-12-31	$8.39B	5.48%
2010-12-31	$7.95B	13.38%
2009-12-31	$7.01B	31.40%
2008-12-31	$5.34B	26.14%
2007-12-31	$4.23B	39.78%
2006-12-31	$3.03B	49.19%
2005-12-31	$2.03B	53.13%
2004-12-31	$1.32B	52.63%
2003-12-31	$867.86M	85.92%
2002-12-31	$466.79M	99.68%
2001-12-31	$233.77M	19.54%
2000-12-31	$195.56M	15.71%
1999-12-31	$169.00M	418.40%
1998-12-31	$32.60M	-18.50%
1997-12-31	$40.00M	19.76%
1996-12-31	$33.40M	1137.04%
1995-12-31	$2.70M	-34.15%
1994-03-31	$4.10M	-2.38%
1993-03-31	$4.20M	-

Gilead Sciences generated $28.75B in revenue during NA 2024, up 6.04% compared to the previous quarter, and up 128.09% compared to the same period a year ago.

Gilead Sciences Revenue by Quarter

Date	Revenue	Change
2024-09-30	$7.55B	8.65%
2024-06-30	$6.95B	3.93%
2024-03-31	$6.69B	-6.03%
2023-12-31	$7.12B	0.92%
2023-09-30	$7.05B	6.83%
2023-06-30	$6.60B	3.89%
2023-03-31	$6.35B	-14.03%
2022-12-31	$7.39B	4.93%
2022-09-30	$7.04B	12.49%
2022-06-30	$6.26B	-5.01%
2022-03-31	$6.59B	-9.03%
2021-12-31	$7.24B	-2.39%
2021-09-30	$7.42B	19.37%
2021-06-30	$6.22B	-3.21%
2021-03-31	$6.42B	-13.45%
2020-12-31	$7.42B	12.83%
2020-09-30	$6.58B	27.88%
2020-06-30	$5.14B	-7.30%
2020-03-31	$5.55B	-5.63%
2019-12-31	$5.88B	4.91%
2019-09-30	$5.60B	-1.42%
2019-06-30	$5.68B	7.65%
2019-03-31	$5.28B	-8.87%
2018-12-31	$5.79B	3.56%
2018-09-30	$5.60B	-0.92%
2018-06-30	$5.65B	11.01%
2018-03-31	$5.09B	-14.47%
2017-12-31	$5.95B	-8.65%
2017-09-30	$6.51B	-8.81%
2017-06-30	$7.14B	9.78%
2017-03-31	$6.50B	-11.13%
2016-12-31	$7.32B	-2.40%
2016-09-30	$7.50B	-3.55%
2016-06-30	$7.78B	-0.23%
2016-03-31	$7.79B	-8.37%
2015-12-31	$8.51B	2.54%
2015-09-30	$8.29B	0.62%
2015-06-30	$8.24B	8.56%
2015-03-31	$7.59B	3.82%
2014-12-31	$7.31B	21.06%
2014-09-30	$6.04B	-7.55%
2014-06-30	$6.53B	30.73%
2014-03-31	$5.00B	60.23%
2013-12-31	$3.12B	12.11%
2013-09-30	$2.78B	0.56%
2013-06-30	$2.77B	9.31%
2013-03-31	$2.53B	-2.19%
2012-12-31	$2.59B	6.66%
2012-09-30	$2.43B	0.89%
2012-06-30	$2.41B	5.38%
2012-03-31	$2.28B	3.73%
2011-12-31	$2.20B	3.71%
2011-09-30	$2.12B	-0.73%
2011-06-30	$2.14B	10.96%
2011-03-31	$1.93B	-3.63%
2010-12-31	$2.00B	3.15%
2010-09-30	$1.94B	0.54%
2010-06-30	$1.93B	-7.60%
2010-03-31	$2.09B	2.63%
2009-12-31	$2.03B	12.82%
2009-09-30	$1.80B	9.36%
2009-06-30	$1.65B	7.62%
2009-03-31	$1.53B	7.16%
2008-12-31	$1.43B	4.15%
2008-09-30	$1.37B	7.29%
2008-06-30	$1.28B	1.59%
2008-03-31	$1.26B	-

Gilead Sciences generated $7.55B in revenue during Q3 2024, up 8.65% compared to the previous quarter, and up 114.41% compared to the same period a year ago.

Gilead Sciences Revenue Breakdown

Gilead Sciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 20	Dec 19	Dec 18
Other Products, Total Other product sales	$889.00M	$859.00M	-	-	-
Trodelvy	$1.31B	$1.06B	-	-	-
Veklury	$1.80B	$2.18B	-	-	-
Products, Other HIV	$19.61B	$18.23B	-	-	-
Cell Therapy Products, Total Cell Therapy Product Sales	$2.38B	$2.24B	-	-	-
Royalty, Contract, And Other	-	$182.00M	$334.00M	$330.00M	$450.00M
Product	-	$26.93B	-	-	-
Oncology Product	-	$2.93B	-	-	-
Hepatitis B Virus / Hepatitis Delta Virus Product	-	$1.02B	-	-	-

Gilead Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Products, Other HIV (75.46%), Cell Therapy Products, Total Cell Therapy Product Sales (9.14%), Veklury (6.92%), Trodelvy (5.06%), and Other Products, Total Other product sales (3.42%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Trodelvy	$674.00M	$332.00M	$309.00M	$298.00M	-	-	-	-	-	-	-	-
Cell Therapy Products, Total Cell Therapy Product Sales	$446.00M	$970.00M	$960.00M	-	-	-	-	-	-	-	-	-
Products, Other HIV	$10.20B	$5.07B	$4.34B	$4.71B	-	-	-	-	-	-	-	-
Other Products, Total Other product sales	$464.00M	$201.00M	$224.00M	$201.00M	-	-	-	-	-	-	-	-
Veklury	$552.00M	$692.00M	$555.00M	$719.00M	-	-	-	-	-	-	-	-
Product	-	-	-	$19.94B	$6.99B	$6.49B	$5.07B	$5.47B	-	-	-	-
Oncology Product	-	-	-	$2.16B	$769.00M	-	-	-	-	-	-	-
Royalty, Contract, And Other	-	-	-	$126.00M	$56.00M	$83.00M	$88.00M	$78.00M	$81.00M	-	-	-
Hepatitis B Virus / Hepatitis Delta Virus Product	-	-	-	$259.00M	-	-	-	-	-	-	-	-

Gilead Sciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Products, Other HIV (82.68%), Trodelvy (5.47%), Veklury (4.48%), Other Products, Total Other product sales (3.76%), and Cell Therapy Products, Total Cell Therapy Product Sales (3.62%).

Gilead Sciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
UNITED STATES	$20.59B	$19.44B	$1.57B	$3.64B	$76.00M
Europe	$4.63B	$4.31B	$702.00M	$1.09B	$241.00M
Other International	-	$3.37B	-	-	-

Gilead Sciences's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (81.63%), and Europe (18.37%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Europe	$2.31B	$1.17B	$1.16B	$1.16B	$1.04B	$52.00M	$111.00M	$142.00M	$130.00M	$126.00M	$304.00M	$334.00M	$109.00M	$264.00M	$388.00M	$71.00M	$937.00M	$62.00M	$48.00M	$63.00M
UNITED STATES	$10.51B	$5.45B	$4.63B	$5.18B	$5.02B	$189.00M	$252.00M	$396.00M	$336.00M	$41.00M	$801.00M	$877.00M	$1.53B	$416.00M	$820.00M	$21.00M	$24.00M	$14.00M	$17.00M	$19.00M
Other International	-	-	$894.00M	$765.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Gilead Sciences's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (81.99%), and Europe (18.01%).

Gilead Sciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRK	Merck	$64.17B	$16.66B
PFE	Pfizer	$63.63B	$17.70B
JNJ	Johnson & Johnson	$61.35B	$22.47B
BMY	Bristol-Myers Squibb	$48.30B	$11.89B
AZN	AstraZeneca	$45.81B	$12.68B
LLY	Eli Lilly and	$45.04B	$11.44B
AMGN	Amgen	$33.42B	$8.50B
GILD	Gilead Sciences	$28.75B	$7.55B
ABBV	AbbVie	-	$14.46B

GILD Revenue FAQ

What is Gilead Sciences’s yearly revenue?

Gilead Sciences's yearly revenue for 2024 was $28.75B, representing an increase of 6.04% compared to 2023. The company's yearly revenue for 2023 was $27.12B, representing a decrease of -0.60% compared to 2022. GILD's yearly revenue for 2022 was $27.28B, representing a decrease of -0.09% compared to 2021.

What is Gilead Sciences’s quarterly revenue?

Gilead Sciences's quarterly revenue for Q3 2024 was $7.55B, a 8.65% increase from the previous quarter (Q2 2024), and a 7.09% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $6.95B, a 3.93% increase from the previous quarter (Q1 2024), and a 5.30% increase year-over-year (Q2 2023). GILD's quarterly revenue for Q1 2024 was $6.69B, a -6.03% decrease from the previous quarter (Q4 2023), and a 5.26% increase year-over-year (Q1 2023).

What is Gilead Sciences’s revenue growth rate?

Gilead Sciences's revenue growth rate for the last 3 years (2022-2024) was 5.40%, and for the last 5 years (2020-2024) was 16.46%.

What are Gilead Sciences’s revenue streams?

Gilead Sciences's revenue streams in c 24 are Other Products, Total Other product sales, Trodelvy, Veklury, Products, Other HIV, and Cell Therapy Products, Total Cell Therapy Product Sales. Other Products, Total Other product sales generated $889M in revenue, accounting 3.42% of the company's total revenue, up 3.49% year-over-year. Trodelvy generated $1.32B in revenue, accounting 5.06% of the company's total revenue, up 23.71% year-over-year. Veklury generated $1.8B in revenue, accounting 6.92% of the company's total revenue, down -17.63% year-over-year. Products, Other HIV generated $19.61B in revenue, accounting 75.46% of the company's total revenue, up 7.58% year-over-year. Cell Therapy Products, Total Cell Therapy Product Sales generated $2.38B in revenue, accounting 9.14% of the company's total revenue, up 6.12% year-over-year.

What is Gilead Sciences’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Gilead Sciences was Products, Other HIV. This segment made a revenue of $19.61B, representing 75.46% of the company's total revenue.